

2023 ASCC

ANNUAL MEETING

Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)

Shubham Pant, MD¹; Jia Fan, MD, PhD²; Do-Youn Oh, MD, PhD³; Hye Jin Choi, MD, PhD⁴; Jin Won Kim, MD, PhD⁵; Heung-Moon Chang, MD, PhD⁶; Lequn Bao, MD⁷; Sun Huichuan, MD, PhD²; Teresa Macarulla, MD, PhD⁸; Feng Xie, MD⁹; Jean-Philippe Metges, MD¹⁰; Jie'er Ying, MD¹¹; John A Bridgewater, MD, PhD¹²; Myung-Ah Lee, MD, PhD¹³; Mohamedtaki A Tejani, MD¹⁴; Emerson Y Chen, MD, MCR¹⁵; Dong Uk Kim, MD¹⁶; Harpreet Wasan, MD, FRCP¹⁷; Michel Ducreux, MD, PhD¹⁸; Yuanyuan Bao, MS¹⁹; Lin Yang, PhD²⁰; JiaFang Ma, MD¹⁹; Phillip M Garfin, MD²⁰; James J Harding, MD²¹

¹MD Anderson Cancer Center, Houston, Texas, US; ²Affiliated Zhongshan Hospital of Fudan University, Shanghai, China; ³Seoul National University Hospital, Seoul, Korea; ⁴Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; ⁵Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea; ⁶Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; ⁷Hubei Cancer Hospital, Hubei, China; ⁸Vall d'Hebrón University Hospital and Vall d'Hebrón Institute of Oncology, Barcelona, Spain; ⁹The Third Affiliated Hospital of the Chinese PLA Naval Military Medical University, Shanghai, China; ¹⁰CHRU de Brest-Hopital Morvan, ARPEGO Network, Brest, France; ¹¹Zhejiang Cancer Hospital, Hangzhou, China; ¹²University College London Cancer Institute, London, UK; ¹³The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea; ¹⁴AdventHealth, Orlando, Florida, US; ¹⁵Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon, US; ¹⁶Pusan National University Hospital, Busan, Korea; ¹⁷Hammersmith Hospital, Imperial College, London, UK; ¹⁸Université Paris-Saclay, Gustave Roussy, Villejuif, France; ¹⁹BeiGene (Beijing) Co., Ltd., Beijing, China; ²⁰Current Jazz Pharmaceuticals employee and former Zymeworks employee during the conduct of the study; ²¹Memorial Sloan Kettering Cancer Center, New York, US

Corresponding Author: spant@mdanderson.org

#ASCO23 PRESENTED BY: Shubham Pant, MD Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Unmet Need in Patients with Biliary Tract Cancer (BTC)

- BTC is uncommon (< 1% of all adult cancers)^{1,2}
- For patients with locally advanced/metastatic BTC, standard 2L+ offers limited clinical benefit
 - ORR 5 15%^{3,4}
 - mPFS 4.0 mo³

#ASCO23

- HER2 amplification/overexpression is observed in a subset of BTC
 - 19 31% of GBC, 17 19% of ECC, 4 5% of ICC^{5,6}
- HER2-targeted therapies have clinical benefit in breast, gastric cancer and lung cancer. There are no approved HER2-targeted therapies for BTC.

2L+ = second line or later (treatment); ECC = extrahepatic cholangiocarcinoma; GBC = gallbladder cancer; HER2 = human epidermal growth factor receptor 2; ICC = intrahepatic cholangiocarcinoma; mPFS = median progression-free survival; ORR = overall response rate.


¹ Valle JW, et al. Lancet 2021;397:428–44. ² Siegel RL, et al. CA Cancer J Clin 2022;72:7–33. ³ Lamarca A, et al. Lancet Oncol 2021;22:690–701. ⁴ Yoo C, et al. Lancet Oncol 2021;22:1560–72. ⁵ Galdy S, et al. Cancer Metastasis Rev 2017;36:141–57. ⁶ Hiraoka N, et al. Hum Path 2020;105:9–19.





Zanidatamab is a HER2-targeted Bispecific Antibody with a Unique Mechanism of Action (MOA)

- Zanidatamab simultaneously binds
 2 separate HER2 molecules in *trans*¹
- Unique binding properties of zanidatamab to HER2 result in multiple MOAs¹
- Preclinical studies demonstrate greater activity than trastuzumab ± pertuzumab¹
- Zanidatamab has shown a manageable safety profile and encouraging antitumor activity in patients with HER2-expressing BTC in a Phase 1 trial²



ECD = extracellular domain

¹ Weisser NE, et al. Nature Commun 2023;14:1394. ² Meric-Bernstam F, et al. Lancet Oncol 2022;23:1558–1570.








HERIZON-BTC-01 Study Design

Phase 2b study of zanidatamab monotherapy in patients with HER2-amplified BTC •



 No prior HER2-targeted therapies

#ASCO23

ECOG PS of 0 or 1

¹ Excludes ampullary

BTC¹

regimen

AE = adverse event; cORR = confirmed objective response rate; CT = computed tomography scan; DCR = disease control rate; DOR = duration of response; ECOG PS = Eastern Cooperative Oncology Group performance status; ICR = independent central review; IHC = immunohistochemistry; IRR = infusion-related reaction; IV = intravenous; MRI = magnetic resonance imaging; OS = overall survival; Q2W = every two weeks; RECIST= Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event.





Enrollment

- Enrollment: September 2020 March 2022
- Sites: 32 in Asia, Europe, North America, & South America
- Data cutoff date for the primary analysis: 10 October 2022
- Study is ongoing but recruitment is complete: 87 patients treated
 - Cohort 1: 80 patients
 - Cohort 2: 7 patients

#ASCO23



* The focus of this presentation will be on HER2-positive BTC (Cohort 1), as Cohort 2 contained a small sample size and did not reveal any responses nor unique safety signals.





Demographics and Baseline Disease Characteristics (Cohort 1)

		(N = 80)
Age, years, median (range)		64 (32, 79)
Sex: Female, n (%)		45 (56.3)
Race, n (%)	Asian	52 (65.0)
	White	23 (28.8)
	Other / Not Reported	5 (6.3)
ECOG PS, n (%)	0	22 (27.5)
	1	58 (72.5)
BTC Subtype, n (%)	GBC	41 (51.3)
	ICC	23 (28.8)
	ECC	16 (20.0)
HER2 Status, n (%)	IHC 2+	18 (22.5)
	IHC 3+	62 (77.5)

		(N = 80)
Disease stage at baseline, n (%)	Stage III	9 (11.3)
	Stage IV	71 (88.8)
Prior therapies in the locally advanced/metastatic setting, median (range)		1 (1, 7)
Regimen received, n (%)*	CISGEM	61 (76.3)
	Fluoropyrimidine-based	27 (33.8)
	PD-1 / PD-L1 inhibitor	21 (26.3)
	Other	5 (6.3)

CISGEM = cisplatin and gemcitabine; PD-1 = programmed cell death protein 1; PD-L1 = programmed death ligand 1.

* Patients are counted at most once under each regimen type received and may be counted in multiple categories



#ASCO23



Disease Response in Patients with HER2-positive BTC (Cohort 1)

• 16 patients had ongoing responses at the time of data cutoff

		Assessment (N = 80)	Assessment (N = 80)	
cORR, % (95% CI)		41.3 (30.4, 52.8)	41.3 (30.4, 52.8)	
Confirmed BOR, n (%)	CR	1 (1.3)	4 (5.0)	
	PR	32 (40.0)	29 (36.3)	
	SD	22 (27.5)	21 (26.3)	
	PD	24 (30.0)	25 (31.3)	
	NE ¹	1 (1.3)	1 (1.3)	
DCR [CR + PR + SD], % (95% CI)		68.8 (57.4, 78.7)	67.5 (56.1, 77.6)	
CBR [CR + PR + (SD ≥ 6 months)], % (95% CI)		47.5 (36.2, 59.0)	47.5 (36.2, 59.0)	

By ICR

By Investigator

CBR = clinical benefit rate; CI = confidence interval; CR = complete response; DCR = disease control rate; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.


¹ NE = one patient died prior to first post-baseline tumor assessment.



#ASCO23



Majority of evaluable patients (68.4%) had a decrease in target lesions (Cohort 1)



*Indicates patients with IHC 2+ status; all other patients had IHC status of 3+. Dotted lines indicate 20% increase and 30% decrease in sum of diameters of target tumors.



#ASCO23


PRESENTED BY: Shubham Pant, MD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



8

Treatment Duration for Patients with Response (CR or PR) or Stable Disease per RECIST v1.1 by ICR (Cohort 1)



Note: Decisions to discontinue zanidatamab were based on investigator assessment. One patient with non-responding tumors was still on treatment.






Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



q

Progression-free Survival in Patients with HER2-positive BTC (Cohort 1)

• OS data not yet mature





#ASCO23



Adverse Events

2023 **ASCO**

ANNUAL MEETING

#ASCO23

	Cohort 1 (N = 80)		Total (N = 87)		
	Any Grade	Grade ≥ 3	Any Grade	Grade ≥ 3	
Any TEAE, n (%)	78 (97.5)	46 (57.5)	84 (96.6)	52 (59.8)	
Any TRAE, n (%)	61 (76.3)	15 (18.8)	63 (72.4)	16 (18.4)	
Serious TRAE, n (%)	7 (8.8)	7 (8.8)	7 (8.0)	7 (8.0)	
TRAEs leading to treatment discontinuation, n (%)	2 (2.5)	1 (1.3)	2 (2.3)	1 (1.1)	
TRAEs leading to death, n (%)	0	0	0	0	
TRAEs, any Grade occurring in $\ge 10\%$ of patients or Grade ≥ 3 in ≥ 2 patients, n (%)					
Diarrhea	32 (40.0)	4 (5.0)	32 (36.8)	4 (4.6)	
IRR	28 (35.0)	1 (1.3)	29 (33.3)	1 (1.1)	
Ejection fraction decreased	8 (10.0)	3 (3.8)	8 (9.2)	3 (3.4)	
Nausea	8 (10.0)	1 (1.3)	8 (9.2)	1 (1.1)	
Anemia	4 (5.0)	2 (2.5)	4 (4.6)	2 (2.3)	

 2 TRAEs led to zanidatamab discontinuation:

11

- I Grade 2 ejection fraction decreased
- 1 Grade 3 pneumonitis
- 3 patients had TRAES that led to dose reductions:
 - I Grade 3 diarrhea
 - I Grade 3 diarrhea and Grade 3 nausea
 - I Grade 2 weight decreased
- No serious TRAEs occurred in more than 1 patient
- No Grade 4 TRAES; no treatment-related deaths

TEAE = treatment-emergent adverse event; TRAE = treatment-related adverse event.





Adverse Events of Special Interest (AESI)

		Cohort 1 (N = 80)		Total (N = 87)	
		Any Grade	Grade ≥ 3	Any Grade	Grade ≥ 3
AESI, n (%)	IRR	28 (35.0)	1 (1.3)	29 (33.3)	1 (1.1)
	Confirmed cardiac events	5 (6.3)	3 (3.8)	5 (5.7)	3 (3.4)
	Non-infectious pulmonary toxicities	1 (1.3)	1 (1.3)	1 (1.1)	1 (1.1)
Select AE, n (%) ¹	Diarrhea	38 (47.5)	6 (7.5)	38 (43.7)	6 (6.9)

¹ AESIs that occurred in at least 1 patient

#ASCO23

- IRR events: all events resolved, generally within 1 day; most occurred with the first cycle of treatment (26/29); most had no recurrence (26/29)
- Confirmed cardiac events: decreased LVEF in 5 patients (5.7%). Patients were clinically asymptomatic, and the events were confounded by pre-existing or concurrent conditions.
- Diarrhea: all but 2 events (both Grade 3) were managed in the outpatient setting, typically with loperamide; most events (87/99) were resolved at the time of data cutoff; median time to resolution of 2.0 days (range, 1 267)





Conclusions

- Zanidatamab demonstrated antitumor activity, including rapid and durable responses, in patients with treatment-refractory HER2-positive BTC
 - cORR per ICR of 41.3%; most responses were identified at first disease assessment
 - Median DOR: 12.9 months
- Zanidatamab demonstrated a manageable and tolerable safety profile
 - Few events led to treatment discontinuation
 - No Grade 4 TRAEs; no deaths were treatment-related
 - Most common AEs were IRRs and diarrhea; predominately low-grade and reversible
- These results support zanidatamab having meaningful clinical benefit and potential as a future treatment option in HER2-positive BTC
 - Additional studies are both planned and active, including zanidatamab in combination with CISGEM

CISGEM = cisplatin and gemcitabine

#ASCO23





We sincerely thank all patients and their caregivers. Thanks to all the investigators, clinical trial researchers, personnel and staff who contributed to the trial in any way.

The HERIZON-BTC-01 study is funded by Zymeworks BC Inc., Jazz Pharmaceuticals, Inc., and BeiGene Ltd.







Full Publication – The Lancet Oncology

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J Harding*, Jia Fan*, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui-Chuan Sun, Teresa Macarulla, Feng Xie, Jean-Phillippe Metges, Jie'er Ying, John Bridgewater, Myung-Ah Lee, Mohamedtaki A Tejani, Emerson Y Chen, Dong Uk Kim, Harpreet Wasan, Michel Ducreux, Yuanyuan Bao, Lisa Boyken, Jiafang Ma, Phillip Garfin, Shubham Pant, on behalf of the HERIZON-BTC-01 study group†

www.thelancet.com/oncology

ANNUAL MEETIN

• Published online June 2, 2023 https://doi.org/10.1016/S1470-2045(23)00242-5

#ASCO23 PRESENTED BY: Shubham Pant, MD Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Articles